Prexasertib

Drug Overview

Prexasertib is an innovative, investigational cancer medication. It belongs to a highly advanced group of medicines known as Targeted Therapy. In the medical world, it is often called a “Smart Drug” because it is designed to seek out and attack a very specific weakness inside cancer cells, rather than attacking all the cells in your body like traditional chemotherapy.

Currently, prexasertib is being closely studied in global clinical trials. It offers hope for patients with cancers that are difficult to treat or have stopped responding to standard treatments, especially certain types of ovarian and breast cancers.

• Generic name: Prexasertib (also known in research as LY2606368)
• US Brand names: None (Currently an investigational agent)
• Drug Class: CHK1 and CHK2 Inhibitor; Targeted Therapy
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Investigational (Not yet FDA approved; available only through clinical trials)

What Is It and How Does It Work? (Mechanism of Action)

To understand how this “Smart Drug” works, imagine a cancer cell as a factory that is constantly dividing to make new cells. Every time a cell divides, it must copy its instruction manual (its DNA). Often, cancer cells make mistakes and damage their own DNA during this process.

Normally, a cell has a “pause button” that stops the factory from dividing until the DNA mistakes are fixed. This pause button is controlled by specific inspector proteins called Checkpoint Kinase 1 (CHK1) and Checkpoint Kinase 2 (CHK2).

At the molecular level, prexasertib works through these precise steps:

1. Blocking the Inspectors: Prexasertib targets and blocks the CHK1 and CHK2 inspector proteins.
2. Removing the Pause Button: Because the inspectors are blocked, the cancer cell loses its ability to pause and fix its broken DNA.
3. Forced Division: The cancer cell is forced to divide before it is ready, carrying massive amounts of broken, damaged DNA into the new cells.
4. Cell Death: The damage becomes too great for the cancer cells to survive. They suffer what scientists call “mitotic catastrophe” and undergo a natural self-destruct process (apoptosis). Healthy cells are usually spared because they do not have the same level of messy, damaged DNA as cancer cells.

FDA-Approved Clinical Indications

Because prexasertib is an investigational drug, it does not currently have official FDA approval for public use outside of clinical trials. It is currently being researched for the following conditions:

Oncological uses (Investigational):

• Ovarian Cancer: Specifically for high-grade serous ovarian cancer, including patients who do not have BRCA mutations (BRCA wild-type) and have become resistant to standard chemotherapy.
• Breast Cancer: Studied in patients with triple-negative breast cancer.
• Squamous Cell Carcinomas: Investigated in head and neck cancers and certain lung cancers.

Non-oncological uses:

• None. This medication is strictly researched for cancer therapy.

Dosage and Administration Protocols

Because prexasertib is an experimental drug, the exact dosage depends on the strict rules of the clinical trial a patient joins. It is given directly into a vein by a healthcare professional.

• 
  Dose adjustments for renal/hepatic insufficiency: Because prexasertib is still in clinical testing, formal dose adjustment rules for patients with liver (hepatic) or kidney (renal) issues are still being established. Trial doctors will perform frequent blood tests. If the liver or kidneys show signs of stress, the doctor will lower the dose or pause the treatment to keep the patient safe.

Clinical Efficacy and Research Results

Recent clinical research (2020–2025) has focused on how well prexasertib works in patients who have run out of standard treatment options.

• Ovarian Cancer Success: In Phase 2 clinical trials for women with hard-to-treat, platinum-resistant ovarian cancer, prexasertib showed very promising results. The Overall Response Rate (ORR) was approximately 29% to 33%, meaning about one-third of the patients saw their tumors shrink significantly.
• Disease Control: For many patients who responded, the drug stabilized the disease, keeping the cancer from growing for an average of 5 to 7 months (Progression-Free Survival), which is a significant achievement for this aggressive type of cancer.
• Combination Therapies: Current ongoing trials are testing prexasertib combined with other targeted therapies (like PARP inhibitors) to see if combining two “Smart Drugs” can increase survival rates even further.

Safety Profile and Side Effects

Because prexasertib pushes cells with damaged DNA to destroy themselves, it can also affect healthy fast-growing cells in the body, particularly in the bone marrow where blood cells are made.

Black Box Warning

• None. (Investigational drugs do not carry an FDA Black Box Warning until they are fully approved and marketed.

Common side effects (>10%)

• Neutropenia: A severe drop in certain white blood cells. This is the most common side effect, occurring in over 70% of patients.
• Thrombocytopenia: A drop in blood platelets, which can cause easy bruising or bleeding.
• Anemia: Low red blood cells, causing extreme tiredness.
• Fatigue: Feeling unusually weak or exhausted.
• Nausea and Vomiting: Mild to moderate stomach upset.

Serious adverse events

• Febrile Neutropenia: A dangerous drop in white blood cells accompanied by a fever. This is a medical emergency because it means the body cannot fight off infections.
• Severe Bleeding: Caused by very low platelet levels.

Management strategies

• White Blood Cell Boosters: To manage neutropenia, doctors almost always prescribe growth factor injections (like G-CSF or pegfilgrastim) a few days after the prexasertib infusion to help the bone marrow quickly make new white blood cells.
• Dose Delays: If blood counts do not recover in time for the next dose, the doctor will delay the treatment for a few days to keep the patient safe.

Research Areas

While prexasertib is not directly a stem cell therapy, it is a major focus in Genomic Cancer Research. Scientists are deeply interested in how to use prexasertib alongside Immunotherapy. By causing massive DNA damage inside the tumor, prexasertib makes the cancer cells look very strange to the immune system. Researchers believe that using this drug can turn a “cold” tumor (one the immune system ignores) into a “hot” tumor, drawing in the body’s natural immune cells to attack the cancer more effectively.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Complete Blood Count (CBC): This is the most critical test. Your white blood cells, red blood cells, and platelets must be at safe levels before every single infusion.
• Comprehensive Metabolic Panel (CMP): To check your baseline liver and kidney function.
• Pregnancy Test: This drug can cause severe harm to an unborn baby. A negative test is required for women of childbearing age.

Precautions during treatment

• Infection Control: Because your white blood cells will drop significantly, you must be extremely careful to avoid infections. Wash your hands frequently and avoid large crowds or sick people.
• Bleeding Precautions: Use a soft-bristled toothbrush and an electric razor to prevent accidental cuts that could bleed heavily.

“Do’s and Don’ts” list

• DO check your temperature every single day. Call your doctor immediately if your temperature reaches 100.4°F (38°C) or higher.
• DO take your anti-nausea medications exactly as prescribed by your care team.
• DO drink plenty of water to stay hydrated and help your body process the medication.
• DON’T take any new over-the-counter pain medicines (like ibuprofen or aspirin) without asking your doctor, as they can increase your risk of bleeding.
• DON’T receive any “live” vaccines (like the nasal flu spray or measles vaccine) while participating in this clinical trial.

Legal Disclaimer

The medical information provided in this guide is for educational and informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Prexasertib (LY2606368) is an investigational drug and is strictly available through approved clinical trials. Always seek the advice of your physician, oncologist, or qualified healthcare provider with any questions you may have regarding a medical condition, treatment options, or clinical trial eligibility.